🏛️ Verified NIH Record • Updated 2026-07-20
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus (NCT05966480)
A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Dose Levels of ESK-001 in Adult Patients With Systemic Lupus Erythematosus
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Alumis Inc
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the clinical efficacy, safety, PK, and PD of multiple dose levels of ESK-001 compared with placebo in adult patients with SLE.
Who can join: Review the eligibility criteria below.
Location: Investigator Site #1046 — Anniston, Alabama
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (169 Sites)
Showing the first 25 of 169 sites.
- Investigator Site #1046 — Anniston, Alabama
- Investigator Site #1104 — La Jolla, California
- Investigator Site #1050 — Los Alamitos, California
- Investigator Site #1168 — Mission Hills, California
- Investigator Site #1174 — Napa, California
- Investigator Site #1061 — Upland, California
- Investigator Site #1048 — Aventura, Florida
- Investigator Site #1063 — Avon Park, Florida
- Investigator Site #1176 — Bradenton, Florida
- Investigator Site #1045 — Clearwater, Florida
- Investigator Site #1055 — Coral Gables, Florida
- Investigator Site #1097 — Coral Springs, Florida
- Investigator Site #1091 — Daytona Beach, Florida
- Investigator Site #1051 — DeBary, Florida
- Investigator Site #1087 — Hollywood, Florida
- Investigator Site #1135 — Kissimmee, Florida
- Investigator Site #1060 — Miami, Florida
- Investigator Site #1093 — Miami, Florida
- Investigator Site #1057 — Miami, Florida
- Investigator Site #1067 — Miami Lakes, Florida
- Investigator Site #1090 — Plantation, Florida
- Investigator Site #1089 — Tampa, Florida
- Investigator Site #1170 — Atlanta, Georgia
- Investigator Site #1052 — College Park, Georgia
- Investigator Site #1204 — Chesterfield, Missouri
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in SLE
- Myocardial Inflammation in Systemic Lupus Erythematosus — Columbus, Ohio
- UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients — Charleston, South Carolina
- CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus — Philadelphia, Pennsylvania
- A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus — Avondale, Arizona
Explore by condition: All SLE clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.